Cytek Biosciences, Inc.Cytek Biosciences, Inc.Cytek Biosciences, Inc.

Cytek Biosciences, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪814.08 M‬USD
−0.08USD
‪−12.15 M‬USD
‪193.01 M‬USD
‪116.78 M‬
Beta (1Y)
2.23
Employees (FY)
676
Change (1Y)
+93 +15.95%
Revenue / Employee (1Y)
‪285.53 K‬USD
Net income / Employee (1Y)
‪−17.97 K‬USD

About Cytek Biosciences, Inc.


CEO
Wen Bin Jiang
Headquarters
Fremont
Founded
1992
FIGI
BBG00D36Q0Z7
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CTKB is 6.32 USD — it has increased by 2.10% in the past 24 hours. Watch Cytek Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cytek Biosciences, Inc. stocks are traded under the ticker CTKB.
CTKB stock has fallen by −1.71% compared to the previous week, the month change is a 3.78% rise, over the last year Cytek Biosciences, Inc. has showed a −32.77% decrease.
We've gathered analysts' opinions on Cytek Biosciences, Inc. future price: according to them, CTKB price has a max estimate of 9.00 USD and a min estimate of 7.00 USD. Watch CTKB chart and read a more detailed Cytek Biosciences, Inc. stock forecast: see what analysts think of Cytek Biosciences, Inc. and suggest that you do with its stocks.
CTKB reached its all-time high on Sep 15, 2021 with the price of 28.70 USD, and its all-time low was 3.80 USD and was reached on Nov 8, 2023. View more price dynamics on CTKB chart.
See other stocks reaching their highest and lowest prices.
CTKB stock is 5.79% volatile and has beta coefficient of 2.23. Track Cytek Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cytek Biosciences, Inc. there?
Today Cytek Biosciences, Inc. has the market capitalization of ‪814.09 M‬, it has decreased by −1.98% over the last week.
Yes, you can track Cytek Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Cytek Biosciences, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
CTKB earnings for the last quarter are 0.06 USD per share, whereas the estimation was 0.01 USD resulting in a 447.26% surprise. The estimated earnings for the next quarter are 0.11 USD per share. See more details about Cytek Biosciences, Inc. earnings.
Cytek Biosciences, Inc. revenue for the last quarter amounts to ‪51.50 M‬ USD, despite the estimated figure of ‪50.70 M‬ USD. In the next quarter, revenue is expected to reach ‪61.49 M‬ USD.
CTKB net income for the last quarter is ‪941.00 K‬ USD, while the quarter before that showed ‪−10.43 M‬ USD of net income which accounts for 109.02% change. Track more Cytek Biosciences, Inc. financial stats to get the full picture.
No, CTKB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 676.00 employees. See our rating of the largest employees — is Cytek Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cytek Biosciences, Inc. EBITDA is ‪−13.47 M‬ USD, and current EBITDA margin is −8.87%. See more stats in Cytek Biosciences, Inc. financial statements.
Like other stocks, CTKB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cytek Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cytek Biosciences, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cytek Biosciences, Inc. stock shows the sell signal. See more of Cytek Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.